Progenity Inc represents a values-driven corporate philosophy focused on improving patient outcomes through innovative molecular testing solutions. The company is committed to enabling personalized medicine, providing physicians and patients with actionable insights to make informed healthcare decisions. Progenity's mission revolves around empowering individuals with the knowledge they need to lead healthier lives. With their comprehensive suite of molecular diagnostic tests, Progenity aims to address unmet medical needs in the fields of women's health, organ transplantation, and gastrointestinal disorders. By leveraging cutting-edge technology and a patient-centric approach, Progenity strives to deliver accurate, timely, and reliable results for healthcare providers and their patients.

Progenity Inc is primarily present in the United States.

Progenity Inc, a leading biotechnology company, has achieved several significant milestones. It successfully completed its initial public offering in June 2020, raising over $122 million in gross proceeds. The company has also expanded its portfolio of innovative molecular testing solutions, empowering healthcare providers and patients with essential genetic insights. Progenity Inc's groundbreaking research and development efforts have resulted in the launch of its flagship product, the Innatal® Prenatal Test, which aids in the detection of common fetal chromosomal disorders. Furthermore, the company has forged strategic partnerships with key industry players, solidifying its position as a pioneer in the field of genetic testing.

Progenity Inc is a prominent company in the healthcare industry, focusing on personalized medicine and diagnostic solutions. Established in 2013, Progenity has quickly risen to prominence due to its innovative products and commitment to improving patient care. With a particular emphasis on genomic testing and precision medicine, Progenity offers a wide range of diagnostic tests, including prenatal and genetic screening. The company's comprehensive approach to healthcare has garnered recognition and partnerships with leading medical institutions. Progenity Inc continues to research, develop, and provide cutting-edge solutions that empower physicians and patients alike, promising a brighter future for personalized healthcare.

The main competitors of Progenity Inc in the market include companies such as Invitae Corporation, Guardant Health, Inc., and Natera, Inc.

Progenity Inc is primarily active in the healthcare industry.

The business model of Progenity Inc revolves around providing innovative diagnostic solutions and precision medicine to improve patient care and outcomes. Progenity leverages its expertise in genomics, molecular biology, and bioinformatics to develop and commercialize specialized tests and diagnostic tools. The company offers a diverse range of services, including genetic testing, carrier screening, prenatal and reproductive health testing, and oncology testing. By combining advanced technologies and clinical expertise, Progenity aims to empower healthcare providers with actionable insights for personalized medicine, early disease detection, and tailored treatment plans. Progenity Inc is committed to revolutionizing patient care through its advanced diagnostic solutions and partnerships with healthcare professionals.

Progenity KGV ir -0,69.

Progenity KUV ir 0.

AlleAktien kvalitātes vērtējums Progenity ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Progenity.

gaidāmā Progenity peļņa ir -95,82 milj. USD.

Progenity Inc is a leading company in prenatal diagnostics and personalized medicine. The company offers a wide range of products and services aimed at improving the health of mother and child during pregnancy and detecting genetic diseases or developmental disorders early on. Progenity Inc has several divisions, including the Progenity Testing Division, which specializes in non-invasive prenatal tests (NIPT), carrier screening, molecular testing, infertility diagnostics, and cancer diagnostics. Progenity's NIPT tests are highly accurate and provide reliable results regarding chromosomal abnormalities in the unborn child. These tests can be performed as early as the 10th week of pregnancy and only require a simple blood sample from the mother. Progenity's carrier screening tests identify genetic mutations that can be passed from parents to the unborn child and can lead to serious diseases. With this test, couples can determine if they are carriers of such mutations and assess the risk of their child developing these conditions. Progenity's molecular testing procedures allow doctors to identify the genetic causes of various diseases and plan more effective treatments. Progenity also offers comprehensive infertility diagnostics, allowing couples to identify the causes of their infertility and plan appropriate treatments. Progenity's Oncology Division offers a comprehensive range of genetic tests for cancer patients. These tests identify the genetic causes of specific types of cancer and enable the planning of individualized, personalized therapies. Progenity Inc also offers innovative solutions for reproductive health. The company has developed a unique platform called Eeva, which allows doctors to track the development of embryos in real time and select the best embryos for implantation. The Eeva platform improves the success rates of IVF treatments and reduces the likelihood of multiple pregnancies. Overall, Progenity Inc relies on innovative technologies and personalized medicine to improve the health of mother and child during pregnancy and facilitate the detection and treatment of genetic diseases. The company pursues a long-term strategy to continue its growth in this dynamic market and solidify its position as a leading company in prenatal diagnostics and personalized medicine.

Progenity izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Progenity vai uzņēmums nedod dividendes.

Progenity ISIN ir US74319F1075.

Progenity WKN ir A2P7FX.

Progenity simbols ir PROG.

Pēdējo 12 mēnešu laikā Progenity maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Progenity plāno maksāt dividendes 0 USD apmērā.

Progenity pašreizējā dividendu rentabilitāte ir .

Progenity maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Progenity pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Progenity tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Progenity apmērā 0 USD, kas tika izmaksāta 9.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.09.2024..

Pēdējās dividendes izmaksa notika 9.09.2024..

Gadā 2023, Progenity izmaksāja 0 USD dividendes.

Progenity dividendes tiek izmaksātas USD.